[en] Among the various chemical classes of monoamine oxidase A inhibitors, phenyloxazolidinone represent one of the major series. The purpose of this paper is to review the experimental (X-ray diffraction, NMR, electronic absorption spectroscopy, lipophilicity studies) and theoretical (quantum chemistry, molecular mechanics, molecular dynamics) studies which have led to the description of the mode of interaction between phenyloxazolidinone inhibitors and the MAO-A enzyme.
Disciplines :
Chemistry
Author, co-author :
Ooms, Frédéric ; Université de Liège - ULiège > HEC Liège Research > HEC Liège Research: Strategy & Performance for the Society ; Facultés Universitaires Notre-Dame de la Paix, Chimie Moléculaire Structurale, Namur, Belgium. ooms@scf.fundp.ac.be
Jegham, S; Facultés Universitaires Notre-Dame de la Paix, Chimie Moléculaire Structurale, Namur, Belgium
George, P; Facultés Universitaires Notre-Dame de la Paix, Chimie Moléculaire Structurale, Namur, Belgium
Durant, F; Facultés Universitaires Notre-Dame de la Paix, Chimie Moléculaire Structurale, Namur, Belgium
Wouters, J; Facultés Universitaires Notre-Dame de la Paix, Chimie Moléculaire Structurale, Namur, Belgium
Language :
English
Title :
Molecular interaction between reversible MAO-A inhibitors and the enzyme. Application to aryloxazolidinone, a prototype series.
Allen F.H., Kennard O., Watson D.G., Brammer L., Orpen G.A., Taylor R. (1987) Tables of bond lengths determined by X-ray and neutron diffraction. Part 1. Bond lengths in organic compounds. J. Chem. Soc. Perkin Trans. 2.
Berlin I., Lecrubier Y. (1996) Food and drug interactions with monoamine oxidase inhibitors - How safe are the newer agents?. CNS Drugs 5:403-413.
Carrupt P.-A., Testa B., Gaillard P. (1997) Computational approaches to lipophilicity: Methods and application., Rev. Comput. Chem. Vol.11 Eds. K. B. Lipkowitz and B. D. Boyd. Wiley-VCH: New York; 241-315.
Curet O., Damoiseau G., Aubin N., Sontag N., Rovei V., Jarreau F.-X. (1996) Befloxatone, a new reversible and selective monoamine oxidase A inhibitor. I. Biochemical profile. J. Pharmacol. Exp. Ther. 277:253-264.
Ding C., Lu X., Nishimura K., Silverman R. (1993) Transformation of monoamine oxidase-B primary amine substrates into time dependent inhibitors. Tertiary amine homologues of primary amine substrates. J. Med. Chem. 36:1711-1715.
Ding C., Silverman R. (1993) Selective inactivation of monoamine oxidase B by aminoethyl 3-chlorobenzyl ether. Bioorg. Med. Chem. Lett. 3:2077-2078.
Ding C., Silverman R. (1993) Transformation of heterocyclic reversible monoamine oxidase-B inactivators into irreversible inactivators by N-methylation. J. Med. Chem. 36:3606-3610.
Dostert P., Strolin Benedetti M., Jalfre M. (1982) Structural modifications in oxazolidinone series leading to type A or B selective monoamine oxidase inhibitors., Monoamine oxidase - Basic and clinical frontiers. Eds. K. Kamijo, E. Usdin and T. Nagatsu. Excerpta Medica: Amsterdam; 197-208.
Dostert P.L., Strolin Benedetti M., Tipton K.F. (1989) Interactions of monoamine oxidase with substrate and inhibitors. Medicinal Research Reviews 9:45-89.
Durant F., Bufkens F., Lefevre F., Evrard G., Michel A. (1985) Molecular structure analysis of monoamine oxidase inhibitors. VII. cis and trans isomers of 3-[4-(5-methoxymethyl-4-methyl-2-oxo-1,3-oxazolidin-3-yl)-phenoxymethyl]benzo nitrile, C20H20N2O5. Acta Cryst 41 C:243-246.
Durant F., Bufkens F., Lefevre F., Lamotte C., Evrard G. (1982) Molecular structure analysis of monoamine oxidase inhibitors IX. 5-(1-methyl)-methoxymethyl-3-[4-[(3-cyanophenyl)-methoxy]phenyl]-2-oxazolidin one (5R*,1S*): C20H20N2O4. Cryst Struct Commun 11:1833-1839.
Durant F., Norberg B., Bufkens F., Evrard G. (1984) Structure moleculaire d'inhibiteurs de monoamine oxydases XII. (methyl-1-methoxymethyl)5-[cyano-3-phenylmethoxy)-4-phenyl]-3-oxazolidinone-2 (5R*,1R*). Bull. Soc. Chim. Fr. 2:183-186.
Gleiter C., Volz H.-P. (1996) MAO-A inhibitors - State of the art. Exp. Opin. Invest. Drugs 5:409-419.
Jegham S., George P. (1998) Monoamine oxidase A and B inhibitors. Exp. Opin. Ther. Patents 8:1143-1150.
Kagaya T., Kajiwara A., Nagato S., Aksaka K., Kubota A. (1996) E2011, a novel, selective and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 278:243-251.
Kato M., Iwata H., Katayama T., Asai H., Narita H., Endo T. (1997) Possible therapeutic effect of T-794, a novel reversible inhibitor of monoamine oxidase-A, on post-stroke emotional disturbances, assessed in animals models of depression. Biol. Pharm. Bull. 20:349-353.
Moureau F., Wouters J., Vercauteren D., Collin S., Evrard G., Durant F., Ducrey F., Koenig J., Jarrreau F. (1992) A reversible monoamine oxidase inhibitor toloxatone: Structural and electronic properties. Eur. J. Med. Chem. 27:939-948.
Moureau F.W.J., Vercauteren D.P. (1994) A reversible monoamine oxidase inhibitor, toloxatone: Spectrophotometric and molecular orbital studies of the interaction with the flavin adenine dinucleotide (FAD). Eur. J. Med. Chem. 29:269-277.
Moureau F.W.J., Depas M., Vercauteren D.P., Durant F., Ducrey F., Koenig J.J., Jarreau F.X. (1995) A reversible monoamine oxidase inhibitor, toloxatone: Comparison of its physiochemical properties with those of other inhibitors including Brofaromine, Harmine, R40519 and Moclobemide. Eur. J. Med. Chem. 30:823-838.
Ooms F., Wouters J., Collin S., Durant F., Jegham S., George P. (1998) Molecular lipophilicity potential by CLIP, a reliable tool for the description of the 3D distribution of lipophilicity: Application to 3-phenyloxazolidin-2-one, a prototype series of reversible MAO-A inhibitors. Bioorg. Med. Chem. Letter 8:1425-1430.
Silverman R.B. (1997) Oxazolidinones, dihydrofuranones, and pyrrolidinones as inactivators and substrates of monoamine oxidase B: Approaches to the design of anti-Parkinsonian agents. Farmaco 52:343-352.
Strolin Benedetti M., Dostert P. (1992) Monoamine oxidase: From physiology and pathophysiology to the design and clinical application of reversible inhibitors. Advances in Drug Research 23:65-125.
Weyler W., Hsu Y.P., Breakefield X.O. (1990) Biochemistry and genetics of monoamine oxidase. Pharmacol. Ther. 47:391-417.
Wouters J., Evrard G., Durant F. (1994) Structure analysis of a reversible monoamine oxidase A inhibitor: 3-4(R)-3-hydroxybutylphenyl-(R)-5-methoxymethyl-1,3-oxazolidin-2-one. Acta Cryst 50 C:1490-1492.
Wouters J., Moureau F., Dory M., Evrard G., Durant F., Ducrey F., Koenig J.J., Jarreau F.X. (1993) Structural and theoretical study of 5-(R)-(methoxymethyl)-3-aryloxazolidin-2-ones, reversible monoamine oxidase inhibitors., Trends in QSAR and molecular modelling 92. Ed. C. Wermuth. ESCOM: Leiden; .
Wouters J., Moureau F., Evrard G., Koenig J.J., Jegham S., George P., Durant F. (1998) A reversible monoamine oxidase A inhibitor, befloxatone: Structural approach of its mechanism of action. Bioorg. Med. Chem., to be submitted; .
Wouters J., Moureau F., Perpete P., Norberg B., Evrard G., Durant F. (1994) Structural characterization of oxidized lumiflavin hydrochloride hydrate: Comparison with the hydrogen bonding at the cofactor of flavoproteins. J. Chem. Cryst. 24:607-614.
Wouters J., Moureau F., Vercauteren D.P., Evrard G., Durant F., Koenig J.J., Ducrey F., Jarreau F.X. (1994) Experimental and theorical study of reversible monoamine oxidase inhibitors: Structural approach of the active site of the enzymes. J. Neural. Transm 41:313-319.
Wouters J., Perpete P., Norberg B., Evrard G., Durant F. (1994) Structure analysis of monoamine oxidase inhibitors, (R)-5-hydroxymethyl- and (R)-5methoxymethyl-3-(4-methoxyphenyl)-oxazolidin-2-one. Acta Cryst. 50 C:97-100.
